David Ashley, MBBS, PhD

Professor of Neurosurgery
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Professor of Medicine
Professor in Pediatrics
Professor in Pathology
Member of the Duke Cancer Institute
Campus mail 203 Research Dr Msrb1, Box 2600, Durham, NC 27710
Phone (919) 684-4164
Email address david.ashley@duke.edu

Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.

In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.

Education and Training

  • Ph.D., University of Melbourne (Australia), 1998
  • M.B.B.S., University of Melbourne (Australia), 1994
  • F.R.A.C.P., Royal Australasian College of Physicians (Australia), 1993

Publications

Khasraw, Mustafa, Kyle M. Walsh, Amy B. Heimberger, and David M. Ashley. “What is the Burden of Proof for Tumor Mutational Burden in gliomas?” Neuro Oncol, November 30, 2020. https://doi.org/10.1093/neuonc/noaa256.

PMID
33252666
Full Text

Broom, Alex, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw. “The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts.” Clin Cancer Res 26, no. 22 (November 15, 2020): 5809–13. https://doi.org/10.1158/1078-0432.CCR-20-2989.

PMID
32816894
Full Text

Ashley, David, Stephen T. Keir, Martin A. Roskoski, Rhian Davies, Ben Williams, Stephen J. P. Damment, and Kelly Conlon. “EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA.” In Neuro Oncology, 22:233–233, 2020.

Scholars@Duke

Randazzo, Dina, Evan Buckley, Herndon James II, Nicole Cort, Mary Affronti, Eric Lipp, Annick Desjardins, et al. “A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS.” In Neuro Oncology, 22:179–179, 2020.

Scholars@Duke

Cort, Nicole, Alex Broom, Katherine Kenny, Alexander Page, Jennifer Durling, Casey Brown, Eric Lipp, et al. “THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING.” In Neuro Oncology, 22:26–26, 2020.

Scholars@Duke

Shen, Erica, Alexander Wallace, Chenan Zhang, Callie Shannon, David Ashley, and Kyle Walsh. “QUANTIFYING THE POTENTIAL PUBLIC HEALTH IMPACT OF VARICELLA ZOSTER VIRUS (VZV) VACCINATION ON GLIOMA INCIDENCE.” In Neuro Oncology, 22:79–79, 2020.

Scholars@Duke

Walsh, Kyle, Joanne Xiu, Giselle Lopez, Daniel Landi, Zachary Reitman, Sandeep Mittal, Andrew Brenner, et al. “BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION.” In Neuro Oncology, 22:5–5, 2020.

Scholars@Duke

Thompson, Eric, Daniel Landi, Eric Lipp, Bea Balajonda, Herndon James II, Evan Buckley, Charlene Flahiff, et al. “PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 22:37–37, 2020.

Scholars@Duke

Low, Justin, Michelle Bowie, Vidya Chandramohan, Rebecca Fuller, Andrea Muscat, Michael Brown, Seethalakshmi Hariharan, et al. “STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA.” In Neuro Oncology, 22:73–73, 2020.

Scholars@Duke

Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, et al. “A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG).” In Neuro Oncology, 22:38–38, 2020.

Scholars@Duke

Pages